Vertex Pharmaceuticals (NASDAQ:VRTX) Trading 9.9% Higher Following Analyst Upgrade

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s share price was up 9.9% on Tuesday after Citigroup raised their price target on the stock from $575.00 to $585.00. Citigroup currently has a buy rating on the stock. Vertex Pharmaceuticals traded as high as $507.00 and last traded at $506.41. Approximately 1,315,084 shares changed hands during mid-day trading, a decline of 10% from the average daily volume of 1,460,381 shares. The stock had previously closed at $460.87.

A number of other analysts have also recently issued reports on VRTX. Oppenheimer boosted their target price on Vertex Pharmaceuticals from $540.00 to $600.00 and gave the stock an “outperform” rating in a report on Tuesday. Weiss Ratings raised shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, February 4th. Canaccord Genuity Group boosted their price objective on shares of Vertex Pharmaceuticals from $411.00 to $441.00 and gave the stock a “hold” rating in a research note on Tuesday, February 17th. Barclays raised their target price on shares of Vertex Pharmaceuticals from $606.00 to $607.00 and gave the company an “overweight” rating in a research note on Tuesday, February 17th. Finally, UBS Group upped their price target on shares of Vertex Pharmaceuticals from $535.00 to $545.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Twenty-three equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $549.18.

Insider Buying and Selling

In related news, EVP Ourania Tatsis sold 260 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total value of $126,451.00. Following the completion of the transaction, the executive vice president directly owned 46,763 shares in the company, valued at approximately $22,743,185.05. This trade represents a 0.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Mark E. Bunnage sold 620 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total value of $301,537.00. Following the sale, the executive vice president owned 7,284 shares in the company, valued at $3,542,573.40. The trade was a 7.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 91,156 shares of company stock worth $42,845,497. 0.20% of the stock is currently owned by insiders.

More Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Povetacicept RAINIER interim analysis met primary and all secondary endpoints, showing meaningful benefit in IgA nephropathy — a potential new commercial franchise that could diversify Vertex’s revenue stream. Vertex Announces Positive Week 36 Interim Analysis Results
• Positive Sentiment: Major analysts raised targets or initiated coverage after the results: Oppenheimer to $600 (Outperform), Jefferies initiated Buy at $580, HC Wainwright raised target to $641, and BMO/William Blair reaffirmed bullish views — signaling increased street confidence in upside from povetacicept and longer-term cash flows. Analyst Coverage & Price Target Moves
• Neutral Sentiment: News and market commentary noted Vertex as a premarket leader and discussed valuation after the move; these pieces provide context for momentum but don’t add new clinical or commercial data. S&P 500 Futures Steady; Vertex Leads
• Neutral Sentiment: Coverage discussing whether the stock remains fairly valued after recent moves may temper near-term upside if investors reassess multiples versus delivery timelines for a new kidney franchise. Is Vertex Still Fairly Priced?
• Negative Sentiment: Recent quarterly results showed only a tiny EPS miss (Feb quarter: $5.03 vs. $5.05 expected) — a reminder that CF franchise growth and near-term financials still matter while new-kidney commercialization timelines, regulatory reviews and competitive dynamics (other IgAN programs) present execution risk.

Institutional Trading of Vertex Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Corient Private Wealth LLC lifted its stake in shares of Vertex Pharmaceuticals by 0.8% in the 4th quarter. Corient Private Wealth LLC now owns 102,570 shares of the pharmaceutical company’s stock worth $46,510,000 after acquiring an additional 839 shares during the period. Mengis Capital Management Inc. bought a new stake in Vertex Pharmaceuticals during the fourth quarter worth approximately $227,000. Rehmann Capital Advisory Group raised its holdings in Vertex Pharmaceuticals by 3.3% during the fourth quarter. Rehmann Capital Advisory Group now owns 1,937 shares of the pharmaceutical company’s stock worth $879,000 after purchasing an additional 61 shares in the last quarter. SHP Wealth Management acquired a new stake in Vertex Pharmaceuticals in the fourth quarter worth approximately $220,000. Finally, S Harris Financial Group LLC bought a new position in Vertex Pharmaceuticals during the 4th quarter valued at $209,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Up 9.5%

The company has a market capitalization of $128.22 billion, a price-to-earnings ratio of 33.02 and a beta of 0.31. The firm has a 50-day moving average price of $467.50 and a 200-day moving average price of $435.79.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing the consensus estimate of $5.05 by ($0.02). Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The firm had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.18 billion. During the same quarter last year, the company earned $3.98 EPS. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.